Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03569631 · ClinicalTrials.gov registry record · Phase 2
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
A Phase 2 study, sponsored by Tetra Discovery Partners.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03569631: Completed Phase 2 study, sponsored by Tetra Discovery Partners.
NCT03569631 is a Phase 2 study that has completed, run by Tetra Discovery Partners. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03569631, a Phase 2 study, has completed, sponsored by Tetra Discovery Partners.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome. Subjects will receive both active treatment with BPN14770 capsules and matching placebo capsules in the course of the study. One treatment will be administered during each of the 12-week study periods.
Interventions
- DRUG Placebo
- DRUG BPN14770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03569631
The ClinicalTrials.gov registry entry for NCT03569631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetra Discovery Partners, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03569631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03569631 about?
NCT03569631 is a clinical study titled "A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome". This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome. Subjects will receive both active treatment with BPN14770 capsules and matching placebo capsules in the course of the...
What is the current status of trial NCT03569631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-07-09. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03569631?
The interventions under investigation include: Placebo (DRUG), BPN14770 (DRUG).
Who is sponsoring clinical trial NCT03569631?
This trial is sponsored by Tetra Discovery Partners, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.